Evidence map›Paper›PMID 41560793›Full record

ReviewMaterials today. Bio2026

Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics - pioneering a new era in precision oncology.

Ayesha Younas, Shuanghu Wang, Muhammad Asad, Abdullah Al Mamun, Saadat Majeed, Ali Sharif, Quan Zhou, Yunxiao Liu, Peiwu Geng, Chuxiao Shao and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Engineered MoSNanomaterials (Basel, Switzerland) · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ayesha YounasKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Afffliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang 323000, China.
Shuanghu WangKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Afffliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang 323000, China.
Muhammad AsadDepartment of Inorganic Chemistry, University of Chemistry and Technology Prague Technická 5, Prague, 616628, Czech Republic.
Abdullah Al MamunKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Afffliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang 323000, China.
Saadat MajeedInstitute of Chemical Sciences, Bahauddin Zakariya University, Multan, 60800, Pakistan.
Ali SharifDepartment of Pharmacology, Institute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University, Lahore, Pakistan.
Quan ZhouKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Afffliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang 323000, China.
Yunxiao LiuKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Afffliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang 323000, China.
Peiwu GengKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Afffliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang 323000, China.
Chuxiao ShaoKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Afffliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang 323000, China.
Jian XiaoKey Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, Central Laboratory of The Lishui Hospital of Wenzhou Medical University, The First Afffliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang 323000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer nanomedicine has evolved from the 1995 landmark approval of Doxil® into a programmable platform of precision oncology. The field now progresses along a coherent continuum that begins with passive enhanced permeability and retention (EPR)-mediated tumor accumulation, advances to active ligand-receptor targeting, and culminates in stimuli-responsive carriers whose cargo is liberated only when triggered by endogenous (acidic pH, redox imbalance, elevated GSH, dysregulated enzymes, ROS) or exogenous (light, magnetic, ultrasound, X-ray, electric) cues intrinsic to the tumor microenvironment (TME). This review maps this continuum, highlighting how the integration of patient-specific multi-omics data with artificial intelligence (AI) is converting tumor heterogeneity into quantitative design rules for nanocarrier optimization, validated in patient-derived organoids. Despite over 15 FDA-approved cancer nanomedicines and a robust clinical pipeline, translation is impeded by biological barriers, protein corona-mediated toxicity, manufacturing scalability issues, and a fragmented regulatory landscape. To bridge this bench-to-bedside chasm, we propose a convergent roadmap: safe-by-design engineering, quality-by-design modular manufacturing, and AI-guided digital twins coupled with micro/nano-robotic delivery for real-time, adaptive dosing. Realizing this vision will transform nanomedicine from an empirical carrier technology into a patient-calibrated, closed-loop therapeutic engine, cementing its role as the frontline of precision oncology.

Indexed as

Artificial intelligenceOmics enhanced nanomedicinePersonalized nanomedicineStimuli-responsive nanoparticlesTranslational challengesTumor microenvironment (TME)

Identifiers

PMID41560793
PMCPMC12813103

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.